ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO281

Percutaneous Renal Biopsy Is Associated With Higher Bleeding Risks in Diabetics: A National Population Based Study

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Chelikani, Vijaya, McLaren Flint Hospital, Flint, Michigan, United States
  • Baral, Nischit, McLaren Flint Hospital, Flint, Michigan, United States
  • Kunadi, Arvind R., McLaren Flint Hospital, Flint, Michigan, United States

Percutaneous renal biopsy (PRB) is required in the diagnosis of glomerular, vascular and tubulointerstitial diseases of the kidney, providing essential information regarding prognosis and management, especially in diabetic nephropathy with atypical features. However, there are complications that develop after a renal biopsy, most commonly in the form of bleeding. The association between diabetes and major bleeding post PRB is not well studied.


This is a retrospective cohort study from PRB hospitalizations between January 1, 2016, and December 31, 2019, using the National Inpatient Sample (NIS). Our study sample included any hospitalizations with PRB procedure with valid information on DM, age 18 years or older, using the ICD 10 procedural and diagnostic codes validated in previous studies. Our outcome of interest of is major bleeding requiring transfusion post procedure.


From 2016 to 2019, a total of 40,177 (weighted N =190,720) hospitalizations with principal or secondary PRB procedure were identified. Among them, 44% (n= 17670) were females and 33% (n=13,318) were diabetics. Mean age was 56.81 ± 15.9 years. Moreover, 57.7% of total PRB were performed in Whites, 20.5% in Blacks, 14.2% in Hispanics, and 3.7% in Asians. Compared to non-DM, those who had DM, were older in age (mean age: 59.6 vs. 54.3; p<0.001), had higher post procedural major bleeding (15% vs 11%, p <0.001) and had similar in-hospital mortality (1% vs 1%, p=0.469). Multivariate regression analysis showed that, compared with non-DM, DM had a significantly increased odds of post procedural major bleeding (aOR: 1.26; 95% CI: 1.18, 1.34; p<0.001) after controlling for age, race, regional location of the hospital, income, and insurance provider. The annual number of PRB procedures done per 100,000 hospitalizations has been increasing at 135.6 in 2016, 138.6 in 2017, 143.9 in 2018 and 146.2 in 2019 (p-trend<0.001).


The number of PRB procedures performed has been increasing over recent years. DM is associated with high bleeding risk after the procedure.